Compare MDBH & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | VNRX |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 38.2M |
| IPO Year | 2023 | N/A |
| Metric | MDBH | VNRX |
|---|---|---|
| Price | $3.63 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 14.7K | ★ 2.1M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | $1,250,398.00 | ★ $1,472,007.00 |
| Revenue This Year | N/A | $55.98 |
| Revenue Next Year | N/A | $420.37 |
| P/E Ratio | $4.75 | ★ N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $3.11 | $0.22 |
| 52 Week High | $7.98 | $0.94 |
| Indicator | MDBH | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 67.56 |
| Support Level | $3.11 | $0.22 |
| Resistance Level | $3.69 | $0.28 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 70.69 | 81.53 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.